Second line therapy in patients with primary biliary cholangitis and inadequate response to UDCA: are we choosing the right target population for clinical trials?

被引：0

作者：

Villamil, Alejandra ^{[1
]}

de la Vina, Daniela ^{[1
]}

Mullen, Eduardo ^{[1
]}

Lucero, Ignacio ^{[1
]}

Sobenko, Natalia ^{[1
]}

Bandi, Juan Carlos ^{[1
]}

机构：

[1] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina

来源：

JOURNAL OF HEPATOLOGY | 2024年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

THU-185

引用

页码：S342 / S343

页数：2

共 50 条

[21] A nomogram based on pretreatment clinical parameters for the prediction of inadequate biochemical response in primary biliary cholangitis
Tian, Siyuan
Liu, Yansheng
Sun, Keshuai
Zhou, Xia
Ma, Shuoyi
Zhang, Miao
Zhou, Xinmin
Wang, Lu
Han, Ying
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2020, 34 (11)
[22] Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy
Montano-Loza, Aldo J.
Corpechot, Christophe
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (11) : 2241 - +
[23] Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group
D'Amato, D.
O'Donnell, S. E.
Cazzagon, N.
Marconi, G.
Gerussi, A.
Cristoferi, L.
Malinverno, F.
Mancuso, C.
Milani, C.
Marzioni, M.
Floreani, A.
Invernizzi, P.
Carbone, M.
DIGESTIVE AND LIVER DISEASE, 2020, 52 : E32 - E32
[24] BEZAFIBRATE AS SECOND LINE TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: A REAL WORLD EXPERIENCE
McCabe, Rebecca
Prince, Martin
Greer, Shaun
Dhaliwal, Harpreet
GUT, 2021, 70 : A147 - A147
[25] Baseline Characteristics and Risk Profiles of 1111 Patients with Primary Biliary Cholangitis (PBC) in Need of Second-Line Therapy
Hirschfield, Gideon
Kowdley, Kris
Kremer, Andreas
Vierling, John
Bowlus, Christopher
Levy, Cynthia
Mayo, Marlyn
Crittenden, Daria
Standen, Mary
Yang, Ke
Choi, Yun-Jung
McWherter, Charles
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S1171 - S1171
[26] Baseline characteristics and risk profiles of 1111 patients with primary biliary cholangitis (PBC) in need of second-line therapy
Hirschfield, Gideon
Kowdley, Kris
Kremer, Andreas E.
Vierling, John M.
Bowlus, Christopher
Levy, Cynthia
Mayo, Marlyn J.
Crittenden, Daria B.
Standen, Mary
Yang, Ke
Choi, Yun-Jung
McWherter, Charles
JOURNAL OF HEPATOLOGY, 2023, 78 : S371 - S372
[27] COMBINED EFFECT OF OBETICHOLIC ACID AND BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND INADEQUATE RESPONSE TO OR INTOLERANCE OF URSODEOXYCHOLIC ACID: RESULTS FROM TWO PHASE 2 CLINICAL TRIALS
Levy, Cynthia
Hejda, Vaclav
Louvet, Alexandre
Younes, Ziad
Mendizabal, Manuel
Bonder, Alan
Zou, Heng
Civitarese, Antonio
Villamil, Alejandra
Nevens, Frederik
HEPATOLOGY, 2024, 79 (02) : E52 - E52
[28] Secondary Treatment of Primary Biliary Cholangitis: Early Prediction of Inadequate Response to Ursodeoxycholic Acid in Patients with PBC
Benjamin D. Liu
Kamran Qureshi
Digestive Diseases and Sciences, 2023, 68 : 346 - 348
[29] Secondary Treatment of Primary Biliary Cholangitis: Early Prediction of Inadequate Response to Ursodeoxycholic Acid in Patients with PBC
Liu, Benjamin D.
Qureshi, Kamran
DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (02) : 346 - 348
[30] Real-world evaluation of second line therapy in Primary Biliary Cholangitis: A multicentre nationwide study
Abbas, Nadir
Culver, Emma
Thorburn, Douglas
Halliday, Neil
Crothers, Hannah
Dyson, Jessica
Aspinall, Richard
Kallis, Yiannis
Smith, Belinda
Patanwala, Imran
McCune, Anne
Chimakurthi, Chenchu
Jones, Rebecca L.
Orrell, Michael
Mells, George
Jones, David
Hirschfield, Gideon
Trivedi, Palak
JOURNAL OF HEPATOLOGY, 2021, 75 : S426 - S427

← 1 2 3 4 5 →